Market Cap 3,000.00
Revenue (ttm) 36.94M
Net Income (ttm) -57.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -154.82%
Debt to Equity Ratio -0.03
Volume 200
Avg Vol 1,032
Day's Range N/A - N/A
Shares Out 32.02M
Stochastic %K 50%
Beta -0.20
Analysts Strong Buy
Price Target N/A

Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric...

Industry: Biotechnology
Sector: Healthcare
Phone: 610-816-6640
Address:
Alexandra House, Office 225/227 The Sweepstakes, Dublin, Ireland
Sandismybeach
Sandismybeach Oct. 25 at 3:35 AM
$NBRVF Fosfomycin and Lefamulin share an unusual coincidence, both could be used to treat bacterial infections in cystic fibrosis patients. Would it be a stretch for Vertex to be interested. Market dynamics make it impossible to commercialize antibiotics successfully, but you turn that concept on its head when you can protect the revenue stream of another wildly successful drug in a totally different market used for a specific patient population. its a stretch a guess, like my theory on net operating loss value.
0 · Reply
normansteve
normansteve Oct. 24 at 3:56 PM
$NBRVF Okay, FDA approved CONTEPO, so how much money will NBRVF shareholders get now, or won't we see a single dollar?
1 · Reply
normansteve
normansteve Oct. 24 at 3:52 PM
0 · Reply
normansteve
normansteve Oct. 24 at 3:51 PM
$NBRVF July 19, 2024 Meitheal gains rights to CONTEPO from Nabriva in North America Meitheal gains access to development and regulatory works, intellectual property rights, technology and related know-how. https://www.pharmaceutical-technology.com/news/meitheal-rights-contepo-nabriva/
0 · Reply
YMoney_
YMoney_ Oct. 24 at 1:53 PM
$NBRVF looks like contepo got approved 10-22-2025 news was posted this morning
3 · Reply
Sandismybeach
Sandismybeach Oct. 23 at 11:13 AM
$NBRVF My account last night showed $1.65 up 1,650,000%. LOl and im still in the red. Its gone this morning. We do have Contepo news, ongoing trial results, and FDA decision possibly by end of year. https://www.biospace.com/press-releases/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025
2 · Reply
sepsis74
sepsis74 Oct. 21 at 1:57 PM
$NBRVF the glitch is still there. Price of $1.31. And the notes say "On 11/14/2025, NBRVF will report fiscal year (FY) 2023 Q3 earnings for the period ending 09/2023."
2 · Reply
sepsis74
sepsis74 Oct. 20 at 11:07 PM
$NBRVF maybe it was just a glitch due to Amazon AWS failing, but my share were marked to $1.31 for half the day. Would be nice if that is real.
1 · Reply
AGG80
AGG80 Oct. 19 at 7:53 PM
$NBRVF what’s the Update?
0 · Reply
kenbkb
kenbkb Oct. 16 at 8:50 PM
$NBRVF Wallstreettrends has called this you got to admit
1 · Reply
Latest News on NBRVF
No data available.
Sandismybeach
Sandismybeach Oct. 25 at 3:35 AM
$NBRVF Fosfomycin and Lefamulin share an unusual coincidence, both could be used to treat bacterial infections in cystic fibrosis patients. Would it be a stretch for Vertex to be interested. Market dynamics make it impossible to commercialize antibiotics successfully, but you turn that concept on its head when you can protect the revenue stream of another wildly successful drug in a totally different market used for a specific patient population. its a stretch a guess, like my theory on net operating loss value.
0 · Reply
normansteve
normansteve Oct. 24 at 3:56 PM
$NBRVF Okay, FDA approved CONTEPO, so how much money will NBRVF shareholders get now, or won't we see a single dollar?
1 · Reply
normansteve
normansteve Oct. 24 at 3:52 PM
0 · Reply
normansteve
normansteve Oct. 24 at 3:51 PM
$NBRVF July 19, 2024 Meitheal gains rights to CONTEPO from Nabriva in North America Meitheal gains access to development and regulatory works, intellectual property rights, technology and related know-how. https://www.pharmaceutical-technology.com/news/meitheal-rights-contepo-nabriva/
0 · Reply
YMoney_
YMoney_ Oct. 24 at 1:53 PM
$NBRVF looks like contepo got approved 10-22-2025 news was posted this morning
3 · Reply
Sandismybeach
Sandismybeach Oct. 23 at 11:13 AM
$NBRVF My account last night showed $1.65 up 1,650,000%. LOl and im still in the red. Its gone this morning. We do have Contepo news, ongoing trial results, and FDA decision possibly by end of year. https://www.biospace.com/press-releases/meitheal-pharmaceuticals-to-present-new-data-in-infectious-disease-portfolio-at-idweek-2025
2 · Reply
sepsis74
sepsis74 Oct. 21 at 1:57 PM
$NBRVF the glitch is still there. Price of $1.31. And the notes say "On 11/14/2025, NBRVF will report fiscal year (FY) 2023 Q3 earnings for the period ending 09/2023."
2 · Reply
sepsis74
sepsis74 Oct. 20 at 11:07 PM
$NBRVF maybe it was just a glitch due to Amazon AWS failing, but my share were marked to $1.31 for half the day. Would be nice if that is real.
1 · Reply
AGG80
AGG80 Oct. 19 at 7:53 PM
$NBRVF what’s the Update?
0 · Reply
kenbkb
kenbkb Oct. 16 at 8:50 PM
$NBRVF Wallstreettrends has called this you got to admit
1 · Reply
normansteve
normansteve Oct. 15 at 8:35 PM
$NBRVF Negotiations have resumed today...... 🤔🤷🏻
1 · Reply
Thomasgs
Thomasgs Oct. 4 at 2:55 PM
$SPY $FIVN I got into this like 10 rears ago at 3.40 or something. Got out at 9. Wish I would of waited for a price target of 200.00 ... oh well $NBRVF this was a dishonest co. Go public get money steal money....
2 · Reply
normansteve
normansteve Oct. 1 at 8:28 PM
$NBRVF today volume 400 🤷🏻
0 · Reply
normansteve
normansteve Sep. 30 at 1:32 PM
$NBRVF Will there be news on October 29th? Could the FDA not approve Contempo? Thanks
0 · Reply
andinvest
andinvest Sep. 17 at 5:58 AM
$NBRVF there was a movement yesterday?
1 · Reply
Sandismybeach
Sandismybeach Sep. 16 at 2:36 PM
$NBRVF interested in buying more shares ahead of the Contempo FDA decision, anyone know how to do that, neither E trade or Robinhood will allow an order for this OTC stock, I have called both trading desks.
3 · Reply
BullDonald
BullDonald Sep. 5 at 11:22 AM
$PTN Like I SAW it Comming... Spana Did it. Today i did not beleive what m seeing sfor a moment .. it's OTC now... Try to get ur ur money some how... befor they dissapear. U dont want to be in a situation lilke : $NBRVF Once in OTC u are Blind whats going on behind the scene. they make money under the table and can sell everything for penny, Retail gets Nothing... BE WARNNED. Third stock that was in my Portfolio once goes.... BK.
2 · Reply
Iknowu2
Iknowu2 Aug. 23 at 4:46 PM
$NBRVF I find it difficult to believe they'll settle for nothing. Consider the accounting firm they hired, which was paid millions and has a team dedicated to this deal. That firm would never get involved with a deal that isn't worth at least $200-$250 million. Given that the company has already spent $30-$40 million since the wind-down, it's clear they aren't aiming for a meager outcome.
2 · Reply
PeonofIndustry
PeonofIndustry Aug. 12 at 1:37 AM
$NBRVF best case scenario.. what are we expecting a share?
2 · Reply
sam2680
sam2680 Aug. 8 at 6:26 PM
$NBRVF another Friday and no news.. maybe 2030? is the year now.
1 · Reply
Iknowu2
Iknowu2 Jul. 29 at 9:12 PM
$NBRVF I do not understand why they still have so many active employees (LinkedIn).Their products are gone, all inventory has been recalled, and there is nothing left. How are they paying these employees, and for what purpose? Why are they wasting whatever, if anything, is left for the shareholders?
1 · Reply
Thomasgs
Thomasgs Jul. 12 at 5:13 PM
$YOU hi I'm new here. What's the good news $SPY $AG going great. Mine stocks leading plus leaving seasonal weakness and this q should be pretty good. $NBRVF hey how much money would I made if I shorted near top ? Was the high around 3 or 4 thousand and now a penny . I need money for fun stuff so can't afford investments like that. That ted guy .... 👊
0 · Reply